CAMP4 THERAPEUTICS CORPORATION CAMP
4.01 USD +0.21 (+5.53%)
As ofNov 16, 2026, 12:42 PM EST
3.58 Day range 4.08
2.90 52-week range 7.75
- YTD
- -34.58%
- 1 year
- -2.20%
News
marketbeat.com CAMP4 Therapeutics Targets 2028 for Key SYNGAP1 Trial Data CAMP4 Therapeutics NASDAQ: CAMP expects data from its Phase 1/2 study of CMP-002, its experimental treatment for SYNGAP1-related disease, in the first half of 2028, CEO Josh Mandel-Brehm said during…
marketbeat.com CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears CAMP4 Therapeutics NASDAQ: CAMP expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to…benzinga.com Camp4 Therapeutics Q3 EPS $(0.37) Misses $(0.18) Estimate, Sales $1.899M Beat $1.850M Estimate Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.18) by 105.56 percent. This is a 32.73 percent increase over losses…
benzinga.com CAMP4 Therapeutics Receives CTA Approval From Regulatory Authorities And Ethics Committees Of Multiple EU Countries To Initiate Global Phase 1/2 ASCEND Clinical Trial Of CMP-002 At Trial Sites In European Union Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002Company…
benzinga.com Raymond James Initiates Coverage On Camp4 Therapeutics with Strong Buy Rating, Announces Price Target of $10 Raymond James analyst Tiago Fauth initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Strong Buy rating and announces Price Target of $10.
